P-56 Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
Titel:
P-56 Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
Auteur:
Macarulla, T. Harding, J. Morizane, C. Ohkawa, K. Ueno, M. Vogel, A. Lamarca, A. Yamamoto, N. Javle, M. Hu, J. Teufel, M. Märten, A. Goyal, L. Yoo, C.